Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment

被引：0
|
作者：
Corassa, Marcelo [1 ]
Abreu, Rodrigo Fonseca [2 ]
Cordeiro de Lima, Vladmir Claudio [1 ]
Torrezan, Giovana Tardim [3 ,4 ]
Cavalher, Felicia Peterson [1 ]
Silva, Tullio Novaes [2 ]
de Oliveira, Thiago Bueno [1 ]
Freitas, Helano Carioca [1 ]
Carraro, Dirce Maria [3 ,4 ]
Costa, Felipe D'Almeida [2 ]
机构：
[1] AC Camargo Canc Ctr, Dept Med Oncol, R Prof Antonio Prudente, Sao Paulo, Brazil
[2] Dept Pathol, R Prof Antonio Prudente, Sao Paulo, Brazil
[3] AC Camargo Canc Ctr, Genom & Mol Biol Grp, Int Res Center CIPE, Sao Paulo, Brazil
[4] Natl Inst Sci & Technol Oncogen INCITO, Sao Paulo, Brazil
来源：
JCO PRECISION ONCOLOGY | 2022年 / 6卷
关键词：
SQUAMOUS-CELL CARCINOMA; HISTOLOGIC TRANSFORMATION; KINASE INHIBITORS; FREQUENCY; CANCER;
D O I：
10.1200/PO.22.00367
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
    Wu, Y-L.
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul Shukor, S.
    Tho, L. M.
    Wang, C-C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E. F. F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
  • [2] Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
    Piotrowska, Zofia
    Hata, Aaron N.
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2441 - 2443
  • [3] The continued osimertinib plus chemotherapy overcoming resistance after histologic transformation in EGFR-mutant lung adenocarcinoma treated with osimertinib.
    Kang, Jin
    Li, Xiang-Meng
    Cheng, Jia-Tao
    Chen, Huajun
    Zhang, Xuchao
    Tu, Hai-Yan
    Zhou, Qing
    Wu, Yi-Long
    Yang, Jin-Ji
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
    Liam, C. K.
    Kim, T. M.
    Yang, J-J.
    Huang, C.
    Voon, P-J.
    Tho, L. M.
    Zhou, Q.
    Wang, J.
    Hayashi, H.
    Tan, D. S. W.
    Danchaivijitr, P.
    Nguyen, V. N.
    Wong, K. H.
    Yang, J. C-H.
    Le, X.
    Ellers-Lenz, B.
    Karachaliou, N.
    Ghori, V.
    Berghoff, K.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
  • [5] First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
    Tan, W.
    Chua, B.
    Yin, D.
    Tan, S. H.
    Tan, D.
    Ang, M.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Lai, G.
    Toh, C. K.
    Tan, E.
    Ng, Q. S.
    Lim, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S607 - S607
  • [6] INSIGHT 2: Tepotinib plus osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
    Smit, E. F.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S894
  • [7] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers
    Qi, Chuang
    Cui, Huanxi
    Chen, Dongsheng
    JAMA ONCOLOGY, 2020, 6 (12)
  • [8] Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib
    Tan, Daniel Shao-Weng
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Lye Mun
    Hayashi, Hidetoshi
    Nhung, Nguyen
    Chia, Puey Ling
    De Marinis, Filippo
    Le, Xiuning
    Karachaliou, Niki
    Brutlach, Sabine
    Adrian, Svenja
    Ellers-Lenz, Barbara
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul, S.
    Mun, T. L.
    Wang, C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
  • [10] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers Reply
    Schoenfeld, Adam J.
    Yu, Helena A.
    JAMA ONCOLOGY, 2020, 6 (12) : 1983 - 1983
12345